share_log

石藥集團：截至2024年3 月31日止三個月之季度業績

CSPC PHARMA: QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2024

Hong Kong Stock Exchange ·  May 27 12:01
Summary by Futu AI
石藥集團於2024年5月27日公佈截至2024年3月31日止三個月之季度業績。報告顯示，集團收入總額達人民幣89.83億元，同比增長11.5%。其中，成藥業務收入增長17.7%，達到人民幣75.61億元，原料產品業務收入下降8.0%，功能食品及其它業務收入下降21.0%。股東應佔基本溢利為人民幣17.24億元，增長11.6%，而財務報表所示之股東應佔溢利為人民幣16.13億元，增長12.9%。每股盈利基本及攤薄均為人民幣14.55分。研發費用達人民幣11.69億元，占成藥業務收入的15.5%，並有超過60個重點在研藥物進入臨床或申報階段。此外，公司於2024年初至今在中國及北美地區獲得多項臨床試驗批件及藥品註冊批件。公司亦積極進行專利申請，截至2024年4月30日，共提交PCT國際申請174件，申請專利1,856件，獲得專利授權921件。
石藥集團於2024年5月27日公佈截至2024年3月31日止三個月之季度業績。報告顯示，集團收入總額達人民幣89.83億元，同比增長11.5%。其中，成藥業務收入增長17.7%，達到人民幣75.61億元，原料產品業務收入下降8.0%，功能食品及其它業務收入下降21.0%。股東應佔基本溢利為人民幣17.24億元，增長11.6%，而財務報表所示之股東應佔溢利為人民幣16.13億元，增長12.9%。每股盈利基本及攤薄均為人民幣14.55分。研發費用達人民幣11.69億元，占成藥業務收入的15.5%，並有超過60個重點在研藥物進入臨床或申報階段。此外，公司於2024年初至今在中國及北美地區獲得多項臨床試驗批件及藥品註冊批件。公司亦積極進行專利申請，截至2024年4月30日，共提交PCT國際申請174件，申請專利1,856件，獲得專利授權921件。
The Petrochemical Group announced on 27 May 2024 its quarterly results for the three months ended 31 March 2024. The report showed that the Group's total revenue reached RMB89.83 billion, up 11.5% year-on-year. Among them, pharmaceutical business revenue grew 17.7% to RMB75.61 billion, raw materials business revenue decreased 8.0% and functional food and other business revenue decreased 21.0%. Shareholders accounted for an underlying profit of RMB17.24 billion, an increase of 11.6%, while the financial statements showed a profit of RMB16.13 billion, an increase of 12.9%. Basic and diluted earnings per share were RMB14.55. R&D expenses totaled RMB11.69 million, accounting for 15.5% of pharmaceutical revenues, and more than 60 key products are in the clinical or filing phase of research drugs. In addition, the Company has received several clinical trial batches and drug registration batches in China and North America in early 2024 to date. The company is also actively applying for patents. As of April 30, 2024, a total of 174 PCT international applications were submitted, 1,856 patent applications and 921 were granted patent licenses.
The Petrochemical Group announced on 27 May 2024 its quarterly results for the three months ended 31 March 2024. The report showed that the Group's total revenue reached RMB89.83 billion, up 11.5% year-on-year. Among them, pharmaceutical business revenue grew 17.7% to RMB75.61 billion, raw materials business revenue decreased 8.0% and functional food and other business revenue decreased 21.0%. Shareholders accounted for an underlying profit of RMB17.24 billion, an increase of 11.6%, while the financial statements showed a profit of RMB16.13 billion, an increase of 12.9%. Basic and diluted earnings per share were RMB14.55. R&D expenses totaled RMB11.69 million, accounting for 15.5% of pharmaceutical revenues, and more than 60 key products are in the clinical or filing phase of research drugs. In addition, the Company has received several clinical trial batches and drug registration batches in China and North America in early 2024 to date. The company is also actively applying for patents. As of April 30, 2024, a total of 174 PCT international applications were submitted, 1,856 patent applications and 921 were granted patent licenses.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.